Modality
Vaccine
MOA
GLP-1/GIP
Target
FLT3
Pathway
PD-1/PD-L1
PVBladder Ca
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
Feb 2017
Phase 2Current
NCT08590954
922 pts·PV
2017-02→TBD·Not yet recruiting
922 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08590954 | Phase 2/3 | PV | Not yet recr... | 922 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 | |
| Motasacituzumab | Olema | NDA/BLA | FLT3 | |
| Tixafotisoran | Mineralys | Phase 3 | FLT3 |